Mumbai, June 11 -- Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems.
Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product.
The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch.
As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource's integrated drug substance and drug product (DS/DP) facility in Bangalore, India.
The collaboration aims to strength...